



**Chunlin Xin** is Vice President of External R&D and Scientific Affairs at CanSino Biologics. His work focuses on translating vaccine innovation into globally relevant products through cross-sector collaboration, technology transfer, and public-health partnership. During the COVID-19 pandemic, he was directly involved in vaccine research and development and supported the localization of vaccine manufacturing in multiple countries. In the post-pandemic period, he has remained actively engaged in global-health-oriented vaccine initiatives, including VLP polio, tuberculosis, and Ebola, as well as collaboration with the WHO/MPP mRNA Technology Transfer Hub. His recent work has focused particularly on advancing VLP polio from scientific promise toward clinical, manufacturing, and future combination-vaccine readiness for the post-eradication era, through collaborations involving partners such as the Gates Foundation, WHO, PATH, and other international stakeholders.